Literature DB >> 12815364

Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities.

Zhicheng Lin1, George R Uhl.   

Abstract

The human dopamine transporter (DAT, SLC6A3) is an important 15 exon gene for dopamine neurotransmission and dopamine recycling. Common exon 15 variable number tandem repeat variants can be associated with attention deficit/hyperactivity disorder. Rarer single nucleotide polymorphisms produce missense variants including V55A and V382A. We now report studies of the functional influences of these DAT protein-coding variants. In COS cell transient-expression assays, V382A displays about half of the dopamine uptake velocity Vmax and cocaine analog binding Bmax values of wildtype DAT. V382A lowers dopamine's potency in inhibiting cocaine analog binding by six-fold. Cells expressing V382A or mixtures of V382A and wildtype DAT both display reduced plasma membrane and increased perinuclear expression, consistent with dominant effects of V328A on expression. V55A expresses normally but reveals a 1.7-fold-lower Km for dopamine uptake. Individuals with these human DAT protein variants could display altered dopamine systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815364     DOI: 10.1038/sj.tpj.6500169

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  7 in total

1.  Genetic influences of dopamine transport gene on alcohol dependence: a pooled analysis of 13 studies with 2483 cases and 1753 controls.

Authors:  Mingqing Xu; Zhicheng Lin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-11-13       Impact factor: 5.067

2.  Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo.

Authors:  Tomas Drgon; Zhicheng Lin; Gene-Jack Wang; Joanna Fowler; Johnfn Pablo; Deborah C Mash; Nora Volkow; George R Uhl
Journal:  Cell Mol Neurobiol       Date:  2006-05-20       Impact factor: 5.046

Review 3.  Regulation of monoamine transporters: Role of transporter phosphorylation.

Authors:  Sammanda Ramamoorthy; Toni S Shippenberg; Lankupalle D Jayanthi
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

Review 4.  Mechanisms of dopamine transporter regulation in normal and disease states.

Authors:  Roxanne A Vaughan; James D Foster
Journal:  Trends Pharmacol Sci       Date:  2013-08-20       Impact factor: 14.819

5.  Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

Authors:  Sean P David; Richard A Brown; George D Papandonatos; Christopher W Kahler; Elizabeth E Lloyd-Richardson; Marcus R Munafò; Peter G Shields; Caryn Lerman; David Strong; Jeanne McCaffery; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2007-08       Impact factor: 4.244

6.  HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum.

Authors:  Jun Zhu; Yaxia Yuan; Narasimha M Midde; Adrian M Gomez; Wei-Lun Sun; Pamela M Quizon; Chang-Guo Zhan
Journal:  J Neurovirol       Date:  2015-10-26       Impact factor: 2.643

Review 7.  Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.

Authors:  Shreyas Bhat; Ali El-Kasaby; Michael Freissmuth; Sonja Sucic
Journal:  Pharmacol Ther       Date:  2020-12-10       Impact factor: 12.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.